The AI-driven pharmaceutical & material IP-generating platform company.

Generative AI built on 16 years of computational expertise and industry-grade, high-quality proprietary data — producing validated, patentable molecules, antibodies, and materials at unprecedented scale.

Get Started Explore Platforms
10B
Virtual Screening / Day
100+
Drug Design Projects
20+
PCT Patents
1B
Parameter Foundation Model
80%
Cost Reduction
10-60%
Wet Lab Hit Rate

About Us

Most Validated AI Therapeutic Design Platform

Ainnocence is the AI-driven pharmaceutical and material IP-generating platform company — a global biotech built on 16 years of computational expertise and industry-grade, high-quality proprietary data, generating validated, patentable molecules, antibodies, and materials at scale.

The Challenge

Costly high-throughput wet lab screening, expensive structure biology, and inaccurate 3D modeling processes.

Our Solution

A radical AI drug discovery system accelerating life-saving therapies with unprecedented speed, deep virtual throughput, and higher success rates.

Proprietary Training Data

Scale That Powers Precision & Accuracy

16 years of computational expertise and industry-grade, high-quality proprietary data — billions of molecules, tens of millions of sequences, and millions of materials, all wet-lab– or DFT-validated — fuel every prediction our AI platforms make. Bigger, cleaner, domain-specific training sets translate directly into higher hit rates, sharper affinities, and fewer false positives at the bench.

2.02B
Chemical Foundation Model
53.5M
Protein Language Model Seqs
9.04M
Material Entries · 6 Categories
4.04M
Antibody Screening Datapoints
16 yrs
Computational Expertise & Data Curation

CarbonAI®

Small Molecule
AI Task Training Data
ADMET 267,872
Target Binding 564,046
Molecular Generation 600,000
Chemical Foundation Model 2,017,000,000

SentinusAI®

Protein / Antibody
AI Task Training Data
Protein Affinity 200,592
Protein Immunogenicity 168,878
Antibody Screening 4,038,529
Protein Language Model 53,463,529

MaterialAI™

Materials
Data Category Entries
Experimental Crystals / ICSD · CSD 1,400,000
DFT-Relaxed Inorganic / MP · OQMD · Alexandria · JARVIS · WBM 5,475,000
Superconductor Tc / SuperCon · NIMS 33,000
Catalyst Surfaces / OC20 · OC22 1,300,000
ML Benchmark Splits / MatBench 132,000
Organic / Organometallic / CCDC 700,000
Total Material Entries 9,040,000

From Scale to Bench Performance

Why our data depth drives accuracy

85.7%
Affinity Maturation Success
Across 42 antibody projects — powered by 4M+ antibody datapoints
10–60%
Wet-Lab Hit Rate
Versus 0.1–1% industry baseline — virtual screening at 2B-record scale

Every datapoint is curated in-house, deduplicated, and stratified by assay quality. Proprietary scale + sequence-based representation = generalization that holds up in the wet lab.

Featured White Paper

Validated by the American Chemical Society

Destructured Drug Discovery — ACS / C&EN White Paper featuring Ainnocence
View PDF →
ACS / C&EN White Paper • 2025

Destructured Drug Discovery

How sequence-based AI speeds and expands the search for new therapeutics — a third-party white paper from the American Chemical Society's C&EN division featuring Ainnocence's platform and founder Lurong Pan.

  • ▸ Published by the American Chemical Society's C&EN division
  • ▸ 80% reduction in early drug discovery cost
  • ▸ Spearman ρ = 0.441 — matches structure-based models at 10,000× lower computational cost
  • ▸ Validated on SARS-CoV-2 broad-neutralizing antibodies
Download White Paper View Online

The Platform

Three Pillars. One Engine.

One platform for biologics, one for chemistry, one for materials — all powered by our proprietary computationally efficient foundation model.

🧬

SentinusAI®

Full-Stack Biologics Design Platform

From sequence to protein to cell — the complete biologics design engine.

Product Modules
  • •Antibody Studio — IgG, Fab, scFv, VHH de novo design & affinity maturation
  • •Peptide Studio — Cyclic, stapled, GLP-1 analog design
  • •RNA Studio — mRNA codon optimization, siRNA design
  • •Cell Studio — Cell line engineering, genome screening
  • •SynBio Studio — Gene design, strain optimization
Customers: Big Pharma, biotech, peptide & RNA therapeutics, cell therapy
Revenue: Target licensing, co-development, FFS design campaigns, platform subscription
⚛

CarbonAI®

End-to-End Molecular Chemistry Platform

Design it, source it naturally, synthesize it, formulate it — one platform.

Product Modules
  • •Molecule Design — Lead gen, scaffold hopping, PROTAC, ADMET
  • •Natural Products — 800K+ NP database, TCM modernization
  • •Synthesis Planner — Multi-step retrosynthesis, reaction prediction
  • •Formulation Engine — Excipient selection, stability, delivery
  • •Cosmetic Actives — Functional skincare, anti-aging peptides
Customers: Pharma small-molecule, CROs, specialty chemicals, cosmetics & personal care
Revenue: FFS + milestone campaigns, platform licensing, B2B SaaS for beauty R&D
🔬

MaterialAI™

AI Materials Discovery Platform

Accelerating advanced materials R&D from years to weeks.

Product Modules
  • •Alloy & Composite Design — High-performance alloys, functional materials, nanomaterials
  • •Semiconductor Materials — Polyimide FCCL, TPU elastomers, process optimization
  • •Crystal Structure Prediction — Stability, phase prediction, process routes
Customers: Semiconductor manufacturers, chemicals (BASF, Dow, DuPont), battery & aerospace
Revenue: Platform licensing, project-based consulting — uncorrelated to pharma
⚡
Computationally Efficient
Foundation Model
The shared engine across all three pillars

Not a product — the foundational technology moat powering all three pillars. Block-circulant FFT layers, κ→1 Hessian conditioning, 3.8× parameter reduction.

Powers SentinusAI® Powers CarbonAI® Powers MaterialAI™
Transformer (Sequence)
→ SentinusAI®
53M protein/DNA sequences · up to 1B params · antibody, peptide, RNA, cell, synbio
Graph Neural Net (Molecular)
→ CarbonAI®
200M chemicals · up to 1B params · small molecule, NP, synthesis, formulation, cosmetics
Hybrid (Crystal + Graph)
→ MaterialAI™
Crystal structure prediction + process optimization · non-pharma customer base

“Ainnocence has three AI platforms — one for biologics, one for chemistry, one for materials — all powered by our proprietary computationally efficient foundation model.”

Research

Scientific Publications

Peer-reviewed research spanning AI, drug discovery, and computational biology

ACS / C&EN White Paper — Destructured Drug Discovery
FEATURED ACS / C&EN White Paper • 2025

Destructured Drug Discovery: How Sequence-Based AI Speeds and Expands the Search for New Therapeutics

An American Chemical Society / C&EN white paper featuring Ainnocence's sequence-based AI platform — bypassing 3D structural modeling to screen billions of drug candidates in hours and cut early-discovery cost by 80%.

Download PDF →
Nature Scientific Reports • 2025

AI-designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains

Demonstrating the power of sequence-based AI for therapeutic antibody design with unprecedented speed and accuracy.
SDPS 2015 • JIDPS 2022 • arXiv 2026

Communication Dynamics Theory Series

Three foundational papers spanning biomolecular systems, periodic table orbitals, and neural network architecture

Pan et al. — Mathematical foundation for all Ainnocence platforms

Multiple Publications

AI Drug Discovery & Virtual Screening

CarbonAI platform, ParaVS framework, antibody affinity maturation, and more

14+ additional peer-reviewed publications

View All 17 Publications

Intellectual Property

Patent Portfolio

20+ PCT patents protecting our AI drug discovery methodologies

20+
PCT Patents Filed
10+
Platform Technologies
Global
Coverage
View Patent Portfolio

Contact

Have Questions? Get in Touch